BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 2786751)

  • 21. Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging.
    Panousis C; Pietersz GA
    Drugs Aging; 1999 Jul; 15(1):1-13. PubMed ID: 10459728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotoxins for the treatment of B-cell lymphomas.
    Ghetie MA; Ghetie V; Vitetta ES
    Mol Med; 1997 Jul; 3(7):420-7. PubMed ID: 9260154
    [No Abstract]   [Full Text] [Related]  

  • 23. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.
    Calvete JA; Newell DR; Charlton CJ; Wright AF
    Br J Cancer; 1993 Jun; 67(6):1310-5. PubMed ID: 8512816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting enzymes for cancer therapy: old enzymes in new roles.
    Deonarain MP; Epenetos AA
    Br J Cancer; 1994 Nov; 70(5):786-94. PubMed ID: 7947082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
    Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental study on chemotherapy using adsorbent charcoal with CDDP administered directly into the mediastinum following esophagectomy.
    Domitsu K; Akiyama S; Ito K; Kiriyama K; Kodera Y; Kondo K; Watanabe T; Takagi H
    Surg Today; 1994; 24(12):1068-72. PubMed ID: 7780228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.
    Reilly RM; Sandhu J; Alvarez-Diez TM; Gallinger S; Kirsh J; Stern H
    Clin Pharmacokinet; 1995 Feb; 28(2):126-42. PubMed ID: 7736688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.
    Byers VS; Austin EB; Clegg JA; Denton G; Gunn B; Hooi D; Hudecz F; Price MR; Baldwin RW
    J Clin Immunol; 1993 Nov; 13(6):406-14. PubMed ID: 7507127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic immunotoxin therapy of cancer: advances and prospects.
    Wawrzynczak EJ
    Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and specificity of a monoclonal antibody-drug conjugate in chemotherapy by intratumoral injection.
    Kitamura K; Takahashi T; Miyagaki T; Yamaoka N; Tsurumi H; Ohtsuji E; Kamiguchi M; Noguchi A; Yamaguchi T
    Jpn J Cancer Res; 1992 Jul; 83(7):769-74. PubMed ID: 1387634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted kill: from umbrellas to monoclonal antibodies.
    Byers VS; Baldwin RW
    J Clin Immunol; 1992 Nov; 12(6):391-405. PubMed ID: 1287032
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies.
    Gould BJ; Borowitz MJ; Groves ES; Carter PW; Anthony D; Weiner LM; Frankel AE
    J Natl Cancer Inst; 1989 May; 81(10):775-81. PubMed ID: 2785605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
    Weiner LM; O'Dwyer J; Kitson J; Comis RL; Frankel AE; Bauer RJ; Konrad MS; Groves ES
    Cancer Res; 1989 Jul; 49(14):4062-7. PubMed ID: 2786751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.